Nonetheless, our work primarily tested a PARylation inhibitor, and future studies will be needed to evaluate whether PARP‐trapping inhibitors elicit similar or even stronger resistance mechanisms in IDH‐mutant gliomas. Here, IDH1 is linked to glioma.